查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1951770

胎盤幹細胞療法治療神經系統疾病市場分析及預測（至2035年）：按類型、產品、服務、技術、應用、最終用戶、流程、階段、解決方案和治療方法

Placental Stem Cell Therapy for Neurological Disorders Market Analysis and Forecast to 2035: Type, Product, Services, Technology, Application, End User, Process, Stage, Solutions, Mode
出版日期: | 出版商: Global Insight Services | 英文 326 Pages | 商品交期: 3-5個工作天內

價格
簡介目錄

用於治療神經系統疾病的胎盤幹細胞療法市場預計將從2024年的4.423億美元成長到2034年的23.259億美元，複合年成長率約為31.7%。該市場涵蓋利用胎盤組織來源的幹細胞來治療神經系統疾病。這種創新方法利用胎盤幹細胞的再生能力來修復受損的神經組織並改善神經功能。推動市場成長的因素包括神經系統疾病盛行率的上升、幹細胞研究的進步以及再生醫學領域投資的增加。關鍵趨勢包括個人化治療、監管發展和策略研發合作。

受再生醫學的進步和神經系統疾病盛行率不斷上升的推動，胎盤幹細胞治療神經系統疾病市場預計將迎來顯著成長。治療應用領域是推動市場成長的主要動力，尤其是在阿茲海默症和帕金森氏症的治療方面，已展現出令人鼓舞的成果。這些治療方法在滿足未被滿足的醫療需求方面發揮關鍵作用。研究領域則受益於胎盤幹細胞在神經發生和神經修復方面潛力的持續探索。臨床試驗和研究舉措的投資不斷增加，也為該領域的成長提供了支持。在各個細分領域中，自體幹細胞療法因其免疫排斥風險較低且符合倫理考量，已成為表現最佳的療法。異體移植療法憑藉其可擴展性和可及性優勢，位居第二，使其成為許多臨床應用的理想選擇。幹細胞採集和處理技術的創新進一步提升了這些治療方法的療效和安全性，促進了其在醫療保健領域的廣泛應用。

市場區隔
類型 同種異體、自體
產品 冷凍保存的胎盤幹細胞，新鮮胎盤幹細胞
服務 幹細胞庫、幹細胞擴增、幹細胞分化、諮詢服務
科技 細胞培養技術、3D生物列印、微流體技術
目的 帕金森氏症、阿茲海默症、多發性硬化症、中風、腦性麻痹、脊髓損傷
最終用戶 醫院、專科診所、研究機構、生物製藥公司
流程 分離、增殖、分化和冷凍保存
步 臨床前研究、臨床試驗與商業化
解決方案 治療方案、診斷方案
治療方法 侵入性、非侵入性

用於治療神經系統疾病的胎盤幹細胞療法市場正經歷市場佔有率、定價和產品創新方面的動態變化。該市場的特點是領先的生物技術公司之間競爭激烈，每家公司都透過策略性的產品發布來爭奪市場主導地位。定價策略受到治療方法的先進性和研發成本的影響。該行業致力於改善患者預後，這推動了具有更高療效和安全性潛力的新型治療方案的推出。在人們對幹細胞療法的認知和接受度不斷提高的推動下，市場呈現出成長跡象。隨著主要參與者尋求相互比較並獲得競爭優勢，市場競爭日益加劇。法規結構發揮著至關重要的作用，北美和歐洲嚴格的政策塑造著市場動態。這些法規確保了安全性和有效性，並影響市場進入和擴大策略。此外，旨在加速創新的合作與夥伴關係也豐富了市場。新興市場在有利的法規環境和不斷成長的醫療保健投資的推動下，提供了盈利的機會。隨著生物技術的進步為變革性治療方法鋪平道路，未來前景一片光明。

主要趨勢和促進因素：

受再生醫學進步和神經系統疾病盛行率上升的推動，用於治療神經系統疾病的胎盤幹細胞療法市場正經歷強勁成長。一個關鍵趨勢是開發具有治療潛在病因而非僅僅緩解症狀潛力的創新幹細胞治療方法。這一轉變吸引了來自公共和私營部門的大量投資，加速了研發進程。此外，隨著監管機構日益認可幹細胞療法的潛力，一個更有利的法規結構正在形成。這加快了核准流程，鼓勵更多公司進入市場。另一個促進因素是醫療專業人員和患者對幹細胞療法的認知和接受度不斷提高，這促進了治療方法的廣泛應用。此外，學術機構和生物技術公司之間的合作正在推動創新並拓展治療產品線。新興市場蘊藏著許多機遇，這些市場的醫療基礎設施正在快速改善，對先進療法的需求旺盛。能夠成功應對監管環境並證明療效和安全性的公司將佔據有利地位，最大限度地掌握這些機會。

目錄

第1章執行摘要

第2章 市場亮點

第3章 市場動態

  • 宏觀經濟分析
  • 市場趨勢
  • 市場促進因素
  • 市場機遇
  • 市場限制
  • 複合年均成長率：成長分析
  • 影響分析
  • 新興市場
  • 技術藍圖
  • 戰略框架

第4章 細分市場分析

  • 市場規模及預測：依類型
    • 同種
    • 自有住房
  • 市場規模及預測：依產品分類
    • 冷凍保存的胎盤幹細胞
    • 新鮮胎盤幹細胞
  • 市場規模及預測：依服務分類
    • 幹細胞庫
    • 幹細胞增殖
    • 幹細胞分化
    • 諮詢服務
  • 市場規模及預測：依技術分類
    • 細胞培養技術
    • 3D生物列印
    • 微流體技術
  • 市場規模及預測：依應用領域分類
    • 帕金森氏症
    • 阿茲海默症
    • 多發性硬化症
    • 中風
    • 腦性麻痹
    • 脊髓損傷
  • 市場規模及預測：依最終用戶分類
    • 醫院
    • 專科診所
    • 研究所
    • 生物製藥公司
  • 市場規模及預測：依製程分類
    • 分離
    • 增殖
    • 差異化
    • 冷凍保存
  • 市場規模及預測：依階段分類
    • 臨床前
    • 臨床試驗
    • 商業化
  • 市場規模及預測：按解決方案分類
    • 治療方案
    • 診斷解決方案
  • 市場規模及預測：依治療方法分類
    • 侵入性
    • 非侵入性

第5章 區域分析

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 拉丁美洲
    • 巴西
    • 阿根廷
    • 其他拉丁美洲地區
  • 亞太地區
    • 中國
    • 印度
    • 韓國
    • 日本
    • 澳洲
    • 台灣
    • 亞太其他地區
  • 歐洲
    • 德國
    • 法國
    • 英國
    • 西班牙
    • 義大利
    • 其他歐洲地區
  • 中東和非洲
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 南非
    • 撒哈拉以南非洲
    • 其他中東和非洲地區

第6章 市場策略

  • 需求與供給差距分析
  • 貿易和物流限制
  • 價格、成本和利潤率趨勢
  • 市場滲透率
  • 消費者分析
  • 法規概述

第7章 競爭訊息

  • 市場定位
  • 市場占有率
  • 競爭基準
  • 主要企業的策略

第8章：公司簡介

  • Celularity
  • Pluristem Therapeutics
  • Re Neuron Group
  • Athersys
  • Brain Storm Cell Therapeutics
  • Neuro Generation
  • Stem Cells
  • Stempeutics Research
  • Fate Therapeutics
  • Neuralstem
  • Stem Bio Sys
  • Cytori Therapeutics
  • Brain Xell
  • Kadimastem
  • Promethera Biosciences
  • Medipost
  • Steminent Biotherapeutics
  • Cell Cure Neurosciences
  • Corestem
  • Biostage

第9章：關於我們

簡介目錄
Product Code: GIS26283

Placental Stem Cell Therapy for Neurological Disorders Market is anticipated to expand from $442.3 million in 2024 to $2,325.9 million by 2034, growing at a CAGR of approximately 31.7%. The Placental Stem Cell Therapy for Neurological Disorders Market encompasses treatments utilizing stem cells derived from placental tissue to address neurological conditions. This innovative approach leverages the regenerative potential of placental stem cells to repair damaged neural tissue and improve neurological function. The market is driven by increasing prevalence of neurological disorders, advancements in stem cell research, and growing investment in regenerative medicine. Key trends include personalized therapies, regulatory advancements, and strategic collaborations in research and development.

The Placental Stem Cell Therapy for Neurological Disorders Market is poised for significant growth, fueled by advancements in regenerative medicine and increasing prevalence of neurological conditions. The therapeutic applications segment leads performance, with Alzheimer's and Parkinson's disease therapies showing promising results. These therapies are becoming pivotal in addressing unmet medical needs. The research applications segment follows closely, driven by ongoing studies exploring the potential of placental stem cells in neurogenesis and neural repair. This segment's growth is supported by rising investments in clinical trials and research initiatives. Among sub-segments, autologous stem cell therapies are emerging as top performers due to their reduced risk of immune rejection and ethical considerations. Allogeneic therapies, being the second-highest performers, offer scalability and accessibility advantages, making them attractive for broader clinical applications. Innovations in stem cell harvesting and processing technologies are further enhancing the efficacy and safety profiles of these therapies, contributing to their growing adoption in the healthcare sector.

Market Segmentation
TypeAllogeneic, Autologous
ProductCryopreserved Placental Stem Cells, Fresh Placental Stem Cells
ServicesStem Cell Banking, Stem Cell Expansion, Stem Cell Differentiation, Consulting Services
TechnologyCell Culture Technology, 3D Bioprinting, Microfluidics
ApplicationParkinson's Disease, Alzheimer's Disease, Multiple Sclerosis, Stroke, Cerebral Palsy, Spinal Cord Injury
End UserHospitals, Specialty Clinics, Research Institutes, Biopharmaceutical Companies
ProcessIsolation, Expansion, Differentiation, Cryopreservation
StagePreclinical, Clinical Trials, Commercialization
SolutionsTherapeutic Solutions, Diagnostic Solutions
ModeInvasive, Non-Invasive

The Placental Stem Cell Therapy for Neurological Disorders Market is witnessing dynamic shifts in market share, pricing, and product innovation. The landscape is characterized by robust competition among leading biotechnology firms, each vying for dominance through strategic product launches. Pricing strategies are influenced by the advanced nature of therapies and the costs associated with research and development. This sector is marked by a focus on improving patient outcomes, driving the introduction of novel therapeutic solutions that promise enhanced efficacy and safety. The market is poised for growth, propelled by increasing awareness and acceptance of stem cell therapies. Competition in this market is intense, with key players benchmarking against each other to enhance their competitive edge. Regulatory frameworks play a pivotal role, with stringent policies in North America and Europe shaping market dynamics. These regulations ensure safety and efficacy, influencing market entry and expansion strategies. The market is further enriched by collaborations and partnerships aimed at accelerating innovation. Emerging markets present lucrative opportunities, driven by favorable regulatory environments and rising healthcare investments. The future landscape is promising, with advancements in biotechnology paving the way for transformative therapies.

Geographical Overview:

The placental stem cell therapy market for neurological disorders is witnessing dynamic growth across various regions. North America leads, driven by advanced healthcare infrastructure and increased research funding. The region's focus on innovative therapies and a high prevalence of neurological disorders bolster market expansion. Europe follows, with strong government support and a growing emphasis on regenerative medicine. The increasing incidence of neurological conditions in the aging population further propels market growth. In the Asia Pacific, rapid market expansion is evident, fueled by rising healthcare investments and a growing interest in stem cell research. Countries like China and India are emerging as significant players due to their large patient populations and supportive regulatory frameworks. Latin America and the Middle East & Africa are developing markets with untapped potential. Brazil and South Africa are witnessing increased investments in stem cell research, recognizing its potential to address unmet medical needs and drive economic growth.

Global tariffs and geopolitical risks are significantly influencing the Placental Stem Cell Therapy for Neurological Disorders Market. In Japan and South Korea, the focus is shifting towards enhancing domestic research capabilities and reducing dependency on imports, in response to trade tensions. China is aggressively pursuing self-sufficiency in biotechnological advancements, spurred by export restrictions and a drive for innovation. Taiwan, while a key player in biotech, faces geopolitical challenges that necessitate strategic alliances and diversification of supply chains. The parent market is experiencing robust growth globally, driven by advancements in regenerative medicine and increasing demand for innovative therapies. By 2035, the market is expected to expand significantly, contingent on geopolitical stability and resilient supply chains. Middle East conflicts could exacerbate global supply chain disruptions and elevate energy prices, impacting production costs and timelines.

Key Trends and Drivers:

The Placental Stem Cell Therapy for Neurological Disorders Market is experiencing robust growth, driven by advancements in regenerative medicine and increasing prevalence of neurological disorders. Key trends include the development of innovative stem cell therapies that offer potential cures rather than symptomatic treatments. This shift is attracting significant investment from both public and private sectors, accelerating research and development efforts. Furthermore, regulatory bodies are increasingly recognizing the potential of stem cell therapies, leading to more favorable regulatory frameworks. This is facilitating faster approval processes and encouraging more companies to enter the market. Another driver is the growing awareness and acceptance of stem cell therapies among healthcare professionals and patients, contributing to increased adoption. Additionally, collaborations between academic institutions and biotech companies are fostering innovation and expanding the therapeutic pipeline. Opportunities abound in emerging markets where healthcare infrastructure is rapidly improving, and there is a high demand for advanced medical treatments. Companies that can navigate regulatory landscapes and demonstrate efficacy and safety are well-positioned to capitalize on these opportunities.

Research Scope:

  • Estimates and forecasts the overall market size across type, application, and region.
  • Provides detailed information and key takeaways on qualitative and quantitative trends, dynamics, business framework, competitive landscape, and company profiling.
  • Identifies factors influencing market growth and challenges, opportunities, drivers, and restraints.
  • Identifies factors that could limit company participation in international markets to help calibrate market share expectations and growth rates.
  • Evaluates key development strategies like acquisitions, product launches, mergers, collaborations, business expansions, agreements, partnerships, and R&D activities.
  • Analyzes smaller market segments strategically, focusing on their potential, growth patterns, and impact on the overall market.
  • Outlines the competitive landscape, assessing business and corporate strategies to monitor and dissect competitive advancements.

Our research scope provides comprehensive market data, insights, and analysis across a variety of critical areas. We cover Local Market Analysis, assessing consumer demographics, purchasing behaviors, and market size within specific regions to identify growth opportunities. Our Local Competition Review offers a detailed evaluation of competitors, including their strengths, weaknesses, and market positioning. We also conduct Local Regulatory Reviews to ensure businesses comply with relevant laws and regulations. Industry Analysis provides an in-depth look at market dynamics, key players, and trends. Additionally, we offer Cross-Segmental Analysis to identify synergies between different market segments, as well as Production-Consumption and Demand-Supply Analysis to optimize supply chain efficiency. Our Import-Export Analysis helps businesses navigate global trade environments by evaluating trade flows and policies. These insights empower clients to make informed strategic decisions, mitigate risks, and capitalize on market opportunities.

TABLE OF CONTENTS

1 Executive Summary

  • 1.1 Market Size and Forecast
  • 1.2 Market Overview
  • 1.3 Market Snapshot
  • 1.4 Regional Snapshot
  • 1.5 Strategic Recommendations
  • 1.6 Analyst Notes

2 Market Highlights

  • 2.1 Key Market Highlights by Type
  • 2.2 Key Market Highlights by Product
  • 2.3 Key Market Highlights by Services
  • 2.4 Key Market Highlights by Technology
  • 2.5 Key Market Highlights by Application
  • 2.6 Key Market Highlights by End User
  • 2.7 Key Market Highlights by Process
  • 2.8 Key Market Highlights by Stage
  • 2.9 Key Market Highlights by Solutions
  • 2.10 Key Market Highlights by Mode

3 Market Dynamics

  • 3.1 Macroeconomic Analysis
  • 3.2 Market Trends
  • 3.3 Market Drivers
  • 3.4 Market Opportunities
  • 3.5 Market Restraints
  • 3.6 CAGR Growth Analysis
  • 3.7 Impact Analysis
  • 3.8 Emerging Markets
  • 3.9 Technology Roadmap
  • 3.10 Strategic Frameworks
    • 3.10.1 PORTER's 5 Forces Model
    • 3.10.2 ANSOFF Matrix
    • 3.10.3 4P's Model
    • 3.10.4 PESTEL Analysis

4 Segment Analysis

  • 4.1 Market Size & Forecast by Type (2020-2035)
    • 4.1.1 Allogeneic
    • 4.1.2 Autologous
  • 4.2 Market Size & Forecast by Product (2020-2035)
    • 4.2.1 Cryopreserved Placental Stem Cells
    • 4.2.2 Fresh Placental Stem Cells
  • 4.3 Market Size & Forecast by Services (2020-2035)
    • 4.3.1 Stem Cell Banking
    • 4.3.2 Stem Cell Expansion
    • 4.3.3 Stem Cell Differentiation
    • 4.3.4 Consulting Services
  • 4.4 Market Size & Forecast by Technology (2020-2035)
    • 4.4.1 Cell Culture Technology
    • 4.4.2 3D Bioprinting
    • 4.4.3 Microfluidics
  • 4.5 Market Size & Forecast by Application (2020-2035)
    • 4.5.1 Parkinson's Disease
    • 4.5.2 Alzheimer's Disease
    • 4.5.3 Multiple Sclerosis
    • 4.5.4 Stroke
    • 4.5.5 Cerebral Palsy
    • 4.5.6 Spinal Cord Injury
  • 4.6 Market Size & Forecast by End User (2020-2035)
    • 4.6.1 Hospitals
    • 4.6.2 Specialty Clinics
    • 4.6.3 Research Institutes
    • 4.6.4 Biopharmaceutical Companies
  • 4.7 Market Size & Forecast by Process (2020-2035)
    • 4.7.1 Isolation
    • 4.7.2 Expansion
    • 4.7.3 Differentiation
    • 4.7.4 Cryopreservation
  • 4.8 Market Size & Forecast by Stage (2020-2035)
    • 4.8.1 Preclinical
    • 4.8.2 Clinical Trials
    • 4.8.3 Commercialization
  • 4.9 Market Size & Forecast by Solutions (2020-2035)
    • 4.9.1 Therapeutic Solutions
    • 4.9.2 Diagnostic Solutions
  • 4.10 Market Size & Forecast by Mode (2020-2035)
    • 4.10.1 Invasive
    • 4.10.2 Non-Invasive

5 Regional Analysis

  • 5.1 Global Market Overview
  • 5.2 North America Market Size (2020-2035)
    • 5.2.1 United States
      • 5.2.1.1 Type
      • 5.2.1.2 Product
      • 5.2.1.3 Services
      • 5.2.1.4 Technology
      • 5.2.1.5 Application
      • 5.2.1.6 End User
      • 5.2.1.7 Process
      • 5.2.1.8 Stage
      • 5.2.1.9 Solutions
      • 5.2.1.10 Mode
    • 5.2.2 Canada
      • 5.2.2.1 Type
      • 5.2.2.2 Product
      • 5.2.2.3 Services
      • 5.2.2.4 Technology
      • 5.2.2.5 Application
      • 5.2.2.6 End User
      • 5.2.2.7 Process
      • 5.2.2.8 Stage
      • 5.2.2.9 Solutions
      • 5.2.2.10 Mode
    • 5.2.3 Mexico
      • 5.2.3.1 Type
      • 5.2.3.2 Product
      • 5.2.3.3 Services
      • 5.2.3.4 Technology
      • 5.2.3.5 Application
      • 5.2.3.6 End User
      • 5.2.3.7 Process
      • 5.2.3.8 Stage
      • 5.2.3.9 Solutions
      • 5.2.3.10 Mode
  • 5.3 Latin America Market Size (2020-2035)
    • 5.3.1 Brazil
      • 5.3.1.1 Type
      • 5.3.1.2 Product
      • 5.3.1.3 Services
      • 5.3.1.4 Technology
      • 5.3.1.5 Application
      • 5.3.1.6 End User
      • 5.3.1.7 Process
      • 5.3.1.8 Stage
      • 5.3.1.9 Solutions
      • 5.3.1.10 Mode
    • 5.3.2 Argentina
      • 5.3.2.1 Type
      • 5.3.2.2 Product
      • 5.3.2.3 Services
      • 5.3.2.4 Technology
      • 5.3.2.5 Application
      • 5.3.2.6 End User
      • 5.3.2.7 Process
      • 5.3.2.8 Stage
      • 5.3.2.9 Solutions
      • 5.3.2.10 Mode
    • 5.3.3 Rest of Latin America
      • 5.3.3.1 Type
      • 5.3.3.2 Product
      • 5.3.3.3 Services
      • 5.3.3.4 Technology
      • 5.3.3.5 Application
      • 5.3.3.6 End User
      • 5.3.3.7 Process
      • 5.3.3.8 Stage
      • 5.3.3.9 Solutions
      • 5.3.3.10 Mode
  • 5.4 Asia-Pacific Market Size (2020-2035)
    • 5.4.1 China
      • 5.4.1.1 Type
      • 5.4.1.2 Product
      • 5.4.1.3 Services
      • 5.4.1.4 Technology
      • 5.4.1.5 Application
      • 5.4.1.6 End User
      • 5.4.1.7 Process
      • 5.4.1.8 Stage
      • 5.4.1.9 Solutions
      • 5.4.1.10 Mode
    • 5.4.2 India
      • 5.4.2.1 Type
      • 5.4.2.2 Product
      • 5.4.2.3 Services
      • 5.4.2.4 Technology
      • 5.4.2.5 Application
      • 5.4.2.6 End User
      • 5.4.2.7 Process
      • 5.4.2.8 Stage
      • 5.4.2.9 Solutions
      • 5.4.2.10 Mode
    • 5.4.3 South Korea
      • 5.4.3.1 Type
      • 5.4.3.2 Product
      • 5.4.3.3 Services
      • 5.4.3.4 Technology
      • 5.4.3.5 Application
      • 5.4.3.6 End User
      • 5.4.3.7 Process
      • 5.4.3.8 Stage
      • 5.4.3.9 Solutions
      • 5.4.3.10 Mode
    • 5.4.4 Japan
      • 5.4.4.1 Type
      • 5.4.4.2 Product
      • 5.4.4.3 Services
      • 5.4.4.4 Technology
      • 5.4.4.5 Application
      • 5.4.4.6 End User
      • 5.4.4.7 Process
      • 5.4.4.8 Stage
      • 5.4.4.9 Solutions
      • 5.4.4.10 Mode
    • 5.4.5 Australia
      • 5.4.5.1 Type
      • 5.4.5.2 Product
      • 5.4.5.3 Services
      • 5.4.5.4 Technology
      • 5.4.5.5 Application
      • 5.4.5.6 End User
      • 5.4.5.7 Process
      • 5.4.5.8 Stage
      • 5.4.5.9 Solutions
      • 5.4.5.10 Mode
    • 5.4.6 Taiwan
      • 5.4.6.1 Type
      • 5.4.6.2 Product
      • 5.4.6.3 Services
      • 5.4.6.4 Technology
      • 5.4.6.5 Application
      • 5.4.6.6 End User
      • 5.4.6.7 Process
      • 5.4.6.8 Stage
      • 5.4.6.9 Solutions
      • 5.4.6.10 Mode
    • 5.4.7 Rest of APAC
      • 5.4.7.1 Type
      • 5.4.7.2 Product
      • 5.4.7.3 Services
      • 5.4.7.4 Technology
      • 5.4.7.5 Application
      • 5.4.7.6 End User
      • 5.4.7.7 Process
      • 5.4.7.8 Stage
      • 5.4.7.9 Solutions
      • 5.4.7.10 Mode
  • 5.5 Europe Market Size (2020-2035)
    • 5.5.1 Germany
      • 5.5.1.1 Type
      • 5.5.1.2 Product
      • 5.5.1.3 Services
      • 5.5.1.4 Technology
      • 5.5.1.5 Application
      • 5.5.1.6 End User
      • 5.5.1.7 Process
      • 5.5.1.8 Stage
      • 5.5.1.9 Solutions
      • 5.5.1.10 Mode
    • 5.5.2 France
      • 5.5.2.1 Type
      • 5.5.2.2 Product
      • 5.5.2.3 Services
      • 5.5.2.4 Technology
      • 5.5.2.5 Application
      • 5.5.2.6 End User
      • 5.5.2.7 Process
      • 5.5.2.8 Stage
      • 5.5.2.9 Solutions
      • 5.5.2.10 Mode
    • 5.5.3 United Kingdom
      • 5.5.3.1 Type
      • 5.5.3.2 Product
      • 5.5.3.3 Services
      • 5.5.3.4 Technology
      • 5.5.3.5 Application
      • 5.5.3.6 End User
      • 5.5.3.7 Process
      • 5.5.3.8 Stage
      • 5.5.3.9 Solutions
      • 5.5.3.10 Mode
    • 5.5.4 Spain
      • 5.5.4.1 Type
      • 5.5.4.2 Product
      • 5.5.4.3 Services
      • 5.5.4.4 Technology
      • 5.5.4.5 Application
      • 5.5.4.6 End User
      • 5.5.4.7 Process
      • 5.5.4.8 Stage
      • 5.5.4.9 Solutions
      • 5.5.4.10 Mode
    • 5.5.5 Italy
      • 5.5.5.1 Type
      • 5.5.5.2 Product
      • 5.5.5.3 Services
      • 5.5.5.4 Technology
      • 5.5.5.5 Application
      • 5.5.5.6 End User
      • 5.5.5.7 Process
      • 5.5.5.8 Stage
      • 5.5.5.9 Solutions
      • 5.5.5.10 Mode
    • 5.5.6 Rest of Europe
      • 5.5.6.1 Type
      • 5.5.6.2 Product
      • 5.5.6.3 Services
      • 5.5.6.4 Technology
      • 5.5.6.5 Application
      • 5.5.6.6 End User
      • 5.5.6.7 Process
      • 5.5.6.8 Stage
      • 5.5.6.9 Solutions
      • 5.5.6.10 Mode
  • 5.6 Middle East & Africa Market Size (2020-2035)
    • 5.6.1 Saudi Arabia
      • 5.6.1.1 Type
      • 5.6.1.2 Product
      • 5.6.1.3 Services
      • 5.6.1.4 Technology
      • 5.6.1.5 Application
      • 5.6.1.6 End User
      • 5.6.1.7 Process
      • 5.6.1.8 Stage
      • 5.6.1.9 Solutions
      • 5.6.1.10 Mode
    • 5.6.2 United Arab Emirates
      • 5.6.2.1 Type
      • 5.6.2.2 Product
      • 5.6.2.3 Services
      • 5.6.2.4 Technology
      • 5.6.2.5 Application
      • 5.6.2.6 End User
      • 5.6.2.7 Process
      • 5.6.2.8 Stage
      • 5.6.2.9 Solutions
      • 5.6.2.10 Mode
    • 5.6.3 South Africa
      • 5.6.3.1 Type
      • 5.6.3.2 Product
      • 5.6.3.3 Services
      • 5.6.3.4 Technology
      • 5.6.3.5 Application
      • 5.6.3.6 End User
      • 5.6.3.7 Process
      • 5.6.3.8 Stage
      • 5.6.3.9 Solutions
      • 5.6.3.10 Mode
    • 5.6.4 Sub-Saharan Africa
      • 5.6.4.1 Type
      • 5.6.4.2 Product
      • 5.6.4.3 Services
      • 5.6.4.4 Technology
      • 5.6.4.5 Application
      • 5.6.4.6 End User
      • 5.6.4.7 Process
      • 5.6.4.8 Stage
      • 5.6.4.9 Solutions
      • 5.6.4.10 Mode
    • 5.6.5 Rest of MEA
      • 5.6.5.1 Type
      • 5.6.5.2 Product
      • 5.6.5.3 Services
      • 5.6.5.4 Technology
      • 5.6.5.5 Application
      • 5.6.5.6 End User
      • 5.6.5.7 Process
      • 5.6.5.8 Stage
      • 5.6.5.9 Solutions
      • 5.6.5.10 Mode

6 Market Strategy

  • 6.1 Demand-Supply Gap Analysis
  • 6.2 Trade & Logistics Constraints
  • 6.3 Price-Cost-Margin Trends
  • 6.4 Market Penetration
  • 6.5 Consumer Analysis
  • 6.6 Regulatory Snapshot

7 Competitive Intelligence

  • 7.1 Market Positioning
  • 7.2 Market Share
  • 7.3 Competition Benchmarking
  • 7.4 Top Company Strategies

8 Company Profiles

  • 8.1 Celularity
    • 8.1.1 Overview
    • 8.1.2 Product Summary
    • 8.1.3 Financial Performance
    • 8.1.4 SWOT Analysis
  • 8.2 Pluristem Therapeutics
    • 8.2.1 Overview
    • 8.2.2 Product Summary
    • 8.2.3 Financial Performance
    • 8.2.4 SWOT Analysis
  • 8.3 Re Neuron Group
    • 8.3.1 Overview
    • 8.3.2 Product Summary
    • 8.3.3 Financial Performance
    • 8.3.4 SWOT Analysis
  • 8.4 Athersys
    • 8.4.1 Overview
    • 8.4.2 Product Summary
    • 8.4.3 Financial Performance
    • 8.4.4 SWOT Analysis
  • 8.5 Brain Storm Cell Therapeutics
    • 8.5.1 Overview
    • 8.5.2 Product Summary
    • 8.5.3 Financial Performance
    • 8.5.4 SWOT Analysis
  • 8.6 Neuro Generation
    • 8.6.1 Overview
    • 8.6.2 Product Summary
    • 8.6.3 Financial Performance
    • 8.6.4 SWOT Analysis
  • 8.7 Stem Cells
    • 8.7.1 Overview
    • 8.7.2 Product Summary
    • 8.7.3 Financial Performance
    • 8.7.4 SWOT Analysis
  • 8.8 Stempeutics Research
    • 8.8.1 Overview
    • 8.8.2 Product Summary
    • 8.8.3 Financial Performance
    • 8.8.4 SWOT Analysis
  • 8.9 Fate Therapeutics
    • 8.9.1 Overview
    • 8.9.2 Product Summary
    • 8.9.3 Financial Performance
    • 8.9.4 SWOT Analysis
  • 8.10 Neuralstem
    • 8.10.1 Overview
    • 8.10.2 Product Summary
    • 8.10.3 Financial Performance
    • 8.10.4 SWOT Analysis
  • 8.11 Stem Bio Sys
    • 8.11.1 Overview
    • 8.11.2 Product Summary
    • 8.11.3 Financial Performance
    • 8.11.4 SWOT Analysis
  • 8.12 Cytori Therapeutics
    • 8.12.1 Overview
    • 8.12.2 Product Summary
    • 8.12.3 Financial Performance
    • 8.12.4 SWOT Analysis
  • 8.13 Brain Xell
    • 8.13.1 Overview
    • 8.13.2 Product Summary
    • 8.13.3 Financial Performance
    • 8.13.4 SWOT Analysis
  • 8.14 Kadimastem
    • 8.14.1 Overview
    • 8.14.2 Product Summary
    • 8.14.3 Financial Performance
    • 8.14.4 SWOT Analysis
  • 8.15 Promethera Biosciences
    • 8.15.1 Overview
    • 8.15.2 Product Summary
    • 8.15.3 Financial Performance
    • 8.15.4 SWOT Analysis
  • 8.16 Medipost
    • 8.16.1 Overview
    • 8.16.2 Product Summary
    • 8.16.3 Financial Performance
    • 8.16.4 SWOT Analysis
  • 8.17 Steminent Biotherapeutics
    • 8.17.1 Overview
    • 8.17.2 Product Summary
    • 8.17.3 Financial Performance
    • 8.17.4 SWOT Analysis
  • 8.18 Cell Cure Neurosciences
    • 8.18.1 Overview
    • 8.18.2 Product Summary
    • 8.18.3 Financial Performance
    • 8.18.4 SWOT Analysis
  • 8.19 Corestem
    • 8.19.1 Overview
    • 8.19.2 Product Summary
    • 8.19.3 Financial Performance
    • 8.19.4 SWOT Analysis
  • 8.20 Biostage
    • 8.20.1 Overview
    • 8.20.2 Product Summary
    • 8.20.3 Financial Performance
    • 8.20.4 SWOT Analysis

9 About Us

  • 9.1 About Us
  • 9.2 Research Methodology
  • 9.3 Research Workflow
  • 9.4 Consulting Services
  • 9.5 Our Clients
  • 9.6 Client Testimonials
  • 9.7 Contact Us